[Chemotherapeutic combinations of mutually potentiating drugs. 3-Application to primary tumors of the central nervous system].
17 patients suffering from primary tumours of the central nervous system recurring after surgery and/or radiotherapy, received chemotherapy consisting of the administration of VM 26 followed by CCNU. Each cycle of treatment lasted four days and was restarted only after an average interval of 30 days to allow for haematological recovery. All of the patients in the trial have been under treatment for eight months. Five (28 p.cent) are at present in complete remission with no residual clinical, isotopic or radiological signs. In six others there was tumour regression and in four neurological stabilisation. In all those cases where objective tumour regression was obtained functional improvement was noted.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002817:Chordoma / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005354:Fibrosarcoma / Q000188:drug therapy; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D014750:Vincristine
Combinaisons chimiothérapiques de grogues se potentialisant. III. Application aux tumeurs primitives du systeme nerveux central